{"id":"W3135190823","doi":"10.1177/1756286420987941","title":"Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"AbbVie Biotherapeutics; Biogen","keywords":"Medicine; Daclizumab; Multiple sclerosis; BETA (programming language); Relapsing remitting; Internal medicine; Oncology; Immunology; Monoclonal antibody; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008001976,0.0006539605,0.001466134,0.0002706058,0.0004908653,0.001048807,0.0004846014,0.00123102,0.002827242],"category_scores_gemma":[0.004368751,0.0002983988,0.001339942,0.0002985624,0.0005321603,0.0007965117,0.0005205168,0.001340234,0.0006633578],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000502264,"about_ca_system_score_gemma":0.00100574,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002389476,"about_ca_topic_score_gemma":0.0009415008,"domain_scores_codex":[0.9984113,0.0008613209,0.0001686426,0.0001928261,0.0002288083,0.0001371356],"domain_scores_gemma":[0.9957666,0.001145829,0.001426536,0.0004571871,0.0004451158,0.0007586175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8585411,0.01556346,0.0365876,0.001150132,0.00165259,0.0002885624,0.0003464714,0.0007364631,0.01276163,0.0001992166,0.002597317,0.06957552],"study_design_scores_gemma":[0.5042751,0.325843,0.1532616,0.0002956729,0.001624103,0.0004681858,0.0001369809,0.001150737,0.005286284,0.0003137878,0.007270093,0.00007456412],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910425,0.00260173,0.0004482896,0.0001952551,0.00006818509,0.002459763,0.001563315,0.00006087042,0.00156003],"genre_scores_gemma":[0.9899293,0.0007629991,0.002003819,0.0006309783,0.0001513916,0.002722505,0.002400488,0.00001645705,0.001382069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008001976,"threshold_uncertainty_score":0.04231894,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06762489834413932,"score_gpt":0.341432496039235,"score_spread":0.2738075976950957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}